BridgeMD
New treatment option for Weaning from Mechanical Ventilation
Official title Physiological Effect High-flow Tracheal Oxygen on Viscosity of Airway Mucus and Respiratory Effort in Patients Weaning from Invasive Mechanical Ventilation
ClinicalTrials.gov ID: NCT06776939
What this study is testing
- What it's testing
- Rationale: Tracheostomized patients weaning from mechanical ventilation are at risk for dryness of airway mucosa and sputum accumulation during disconnection from mechanical ventilation. High-flow tracheal oxygen (HFTO) is being used as supportive therapy during disconnection sessions in tracheostomized patients weaning from invasive mechanical ventilation (IMV) to limit dryness while maintaining oxygenation.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Inclusion:
- Age ≥18 years
- Weaning from mechanical ventilation with tracheostomy
You likely can't join if
- Longstanding tracheostomy, defined as tracheostomy being present prior to current hospital admission
- Tracheostomy primarily indicated for chronic upper airway obstruction or to secure airway patency due to persistent stupor/coma
- Chronic positive pressure respiratory support at home (excluding night-time continuous positive airway pressure for sleep apnea)
- Mucociliary disease in medical history (e.g. cystic fibrosis, pulmonary ciliary dyskinesia)
- Neuromuscular disease in medical history (excluding ICU-acquired weakness)
- Contra-indication placement oesophageal balloon for measurement of PES, such as:
See the full eligibility criteria
- Inclusion:
- Age ≥18 years
- Weaning from mechanical ventilation with tracheostomy
- Longstanding tracheostomy, defined as tracheostomy being present prior to current hospital admission
- Tracheostomy primarily indicated for chronic upper airway obstruction or to secure airway patency due to persistent stupor/coma
- Chronic positive pressure respiratory support at home (excluding night-time continuous positive airway pressure for sleep apnea)
- Mucociliary disease in medical history (e.g. cystic fibrosis, pulmonary ciliary dyskinesia)
- Neuromuscular disease in medical history (excluding ICU-acquired weakness)
- Contra-indication placement oesophageal balloon for measurement of PES, such as:
- Fractures in mandibular, orbital or ethmoid bone or skull base
- Esophageal varices or surgery in medical history
- Severe bleeding disorders
- Hemoptysis in 72 hours prior to the first disconnection session. Clinically relevant hemoptysis is defined as hemoptysis requiring tracheal/endobronchial or radiologic intervention, or administration of pro-coagulating...
The study team makes the final eligibility decision.
Where it's taking place
- Rotterdam, Netherlands
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rotterdam, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.